One of the largest medical laboratories in New Zealand has adopted Roche NimbleGen's microarray platform, Roche said this week.
Canterbury Health Laboratories will use Roche NimbleGen's CGX cytogenetics arrays for its research on developmental delay and mental retardation. As part of the platform adoption, Christchurch-based Canterbury has implemented the NimbleGen workflow for cytogenetics, including arrays, reagents, instruments, and software, in its core facility, Roche said.
The laboratory will initially use NimbleGen CGX-12 arrays for its research. The whole-genome oligonucleotide arrays enable users to survey more than 200 cytogenetically relevant regions, including more than 675 functionally significant genes. Roche began selling the chips that are based on a design by Signature Genomics, now part of PerkinElmer, last year (BAN 11/10/2009).
Canterbury claims to be the largest medical testing lab on New Zealand's South Island. In addition to its Christchurch headquarters, Canterbury maintains smaller laboratories and collection centers at Ashburton, Burwood, and Princess Margaret Hospital in Christchurch.
Roche said the lab, which specializes in medical and genetic research, including neonatal cytogenetic testing, also services other Asia Pacific regions including Australia.
Financial details of Roche's deal with Canterbury were not discussed.
Have topics you'd like to see covered in BioArray News? Contact the editor at jpetrone [at] genomeweb [.] com.